HIV: A therapeutic advance for resource-limited settings

(ANRS) ANRS 12286 MOBIDIP, a clinical trial running in parallel in three countries in sub-Saharan Africa, shows that dual therapy with lamivudine and a boosted protease inhibitor is effective as second-line treatment in patients infected by HIV with multiple mutations. Such treatment deescalation will reduce costs, side effects, and the need for virological monitoring of patients. The results of this study are published in The Lancet HIV.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news